FDA proposes a faster path for custom gene-editing treatments
Published
Draft guidance would let makers of personalized gene-editing therapies for rare diseases add new patient-specific versions without new clinical trials, if lab tests show they're safe and active. Separately, CMS is expanding a program that negotiates gene therapy deals for Medicaid beyond sickle cell disease.
Source: Becker's Hospital Review
This is a plain-language summary. Read the original source for full details.